競合他社を買収すべきか
in HealthTech & Digital Health

簡潔な答え

買収が失敗する主因は価格ではなく、リスク負担契約と成果帰属の整合です。契約不整合によるエンゲージメント率の乖離と顧客離脱コストは、事前試算で最も見落とされやすい数字です。 デジタルヘルス企業の場合、質問の本質は一般論とは異なります。成果リスクを負う契約が、企業がそのリスクを担えるかを検証できる期間より早く締結されます。12か月の測定期間に対し営業サイクルが11か月であるため、リスク負担収益シェアを無視した回答は確実に誤ります。分析は収益ではなく、エンゲージメント率と粗利益率から始める必要があります。

競合買収の根拠は通常、加入者プールを統合してリスク負担収益シェアを拡大することに置かれます。これは最も実現性が低く、到達が最も遅い効果です。粗利益率の改善は予測しやすく、誠実に見積もった場合、モデルが想定する水準を下回ることが多いです。

成否を左右する数字は統合コストです。PMPM測定期間の整合、成果帰属の調整、既存顧客対応から1年以上にわたって経営資源が奪われる影響です。見積もりが難しく両社の帳簿に現れないため、通常は省かれます。

厳格な検証では、他に安価に構築または購入できない具体的な要素は何か、リスク負担シェアのシナジーが一切実現しなかった場合の事業姿はどうなるかを問います。

これが実際に貴社の問題であるとわかる兆候

この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。

✓ 根拠が双方の加入者におけるリスク負担収益シェアの統合に依存している
✓ 統合は言及されるが、エンゲージメント率と顧客離脱の整合コストはモデル化されていない
✓ 買収動機の一部が既存事業の成果リスク契約停滞にある

通常、事態を悪化させる対応です。 リスク負担収益シェアのシナジーで買収を評価すること。到着は遅れ、規模はモデルを下回り、実現しない場合がほとんどです。

Who this is for — and who it is not

It is for you if you run or finance a digital health company and the rationale leans on cross-selling to each other's customers. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

分析を実際に実行したときの様子

Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.

The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.

This is one move out of a full analysis. Read a complete report — every page, no email required.

エンジンがこの質問に対して行うこと

This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.

この件についてよくある質問

競合の価値はどのように算定するか

2回算定します。単独での価値と、自社にとっての価値です。その差が価値を生みながら支払える上限であり、通常は想定より狭くなります。

コストシナジーと収益シナジー、どちらが信頼できるか

コストシナジーです。管理可能でスケジュールが立てられます。収益シナジーは顧客行動がモデル通りになることに依存し、最も誤りやすい前提です。

買収が失敗する最も多い理由は何か

統合に要する経営資源の消費が予算を上回り、買収の回収期間中に両事業が業績を落とすことです。

Is this different in healthtech & digital health than in other industries?

Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for a digital health company?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.